The trial, completed at the University of Washington Medical Center in Seattle, tested the safety and efficacy of the prototype’s ability to take over the functions of a failed kidney.
During the study, the device effectively cleared patients’ blood of waste products, excess water and salt.
The technology could provide an alternative to conventional hemodialysis for patients with end-stage kidney disease. The prototype holds many advantages to conventional dialysis, including improved mobility during treatment, longer and more frequent treatment sessions and decreased need for strict diet restrictions.
Some technical problems, including excessive formation of carbon dioxide bubbles in the dialysis solution, occurred during the study. Researchers will address these issues through device redesign and refinement before any further long-term studies are conducted.
More articles on supply chain:
Johnson & Johnson ignores pressure to focus on drug production only
3 things to know about Noxilizer’s nitrogen dioxide-based sterilization process
Arizona medical device startup finalist for $250,000 grant
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
